Search / 23 results found

  • Updated

BEVERLY, Mass., Jan. 12, 2021 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, today provided updated financial guidance for the fourth quarter of 2020. The Company expects revenue for the fourth quarter of 2020 to be approximately $120 million, above the $110 million prior guidance. Gross margin of approximately 43% is up from the previous gross margin guidance of 41%. As a result, the Company expects earnings per diluted share of approximately $0.32, up from the previous guidance of approximately $0.21. Cash will be greater than $200 million. Strong performance by our CS&I business contributed to the strong revenue and gross margin.

  • Updated

MARLBOROUGH, Mass., Jan. 12, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales, based upon preliminary unaudited financial information, of approximately $2.71 billion during the fourth quarter of 2020. This represents a decline of approximately (6.8) percent on a reported basis, approximately (8.3) percent on an operational(1) basis and approximately (8.0) percent on an organic(2) basis, all compared to the prior year period. Included within organic results is a negative 370 basis point impact associated with the conversion of U.S. WATCHMAN(TM) customers to a consignment inventory model and transition to the next-generation WATCHMAN FLX(TM) Left Atrial Appendage Closure (LAAC) Device.

WILMINGTON – The last time the Wilmington High Boys Basketball team faced Wakefield, the game was over almost before it even started, as Wakef…